fulvestrant,enzalutamide,letrozole,pf-07220060,midazolam
pfizer
['breast', 'pf-07220060', 'pfizer']
as per the results presented at 2023, 's next-gen cdk4-selective inhibitor pf-07220060 demonstrated remarkable efficacy &amp; favorable safety profile in heavily pretreated hr+her2- metastatic breast cancer patients. for more insights, visit: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry